DiaMedica director granted 40,412 stock options

DiaMedica Therapeutics Inc. director Charles Pauling Semba received a new stock option grant.

Accepted by SEC EDGAR 06/03/2026 - 05:26 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

DiaMedica Therapeutics Inc. director Charles Pauling Semba received a new stock option grant. He was awarded options for 40,412 shares of Voting Common Shares at an exercise price of $5.84 per share. These options are scheduled to vest in four equal quarterly installments and expire on June 1, 2036.

Insider Trade Summary

Grant/Award: 40,412 shares

Grant/Award 1 txn

Insider Semba Charles Pauling

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	40,412	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 40,412 contracts (Direct)

Footnotes (1)

1. F1. Scheduled to vest in four equal quarterly installments.

Key Figures

Option grant size: 40,412 options Exercise price: $5.84 per share Expiration date: June 1, 2036 +1 more

4 metrics

Option grant size 40,412 options Stock Option (right to buy) award to director

Exercise price $5.84 per share Stock option exercise price for Voting Common Shares

Expiration date June 1, 2036 Option term end date

Post-transaction options held 40,412 options Total derivative securities following grant

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, Voting Common Shares, Scheduled to vest in four equal quarterly installments

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Voting Common Shares financial

"underlying_security_title: "Voting Common Shares""

Scheduled to vest in four equal quarterly installments financial

"Footnote: "Scheduled to vest in four equal quarterly installments.""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did DiaMedica Therapeutics (DMAC) disclose on this Form 4?

DiaMedica Therapeutics disclosed that director Charles Pauling Semba received a stock option grant for 40,412 Voting Common Shares. The options were awarded as a compensation-related grant, not an open-market purchase or sale, and give the right to buy shares at a fixed exercise price.

How many DiaMedica Therapeutics (DMAC) options were granted to Charles Pauling Semba?

Charles Pauling Semba was granted options covering 40,412 Voting Common Shares. This entire amount reflects a single compensation-related award, and his total options following this transaction are 40,412, according to the reported holdings after the grant on the Form 4.

What is the exercise price and expiration date of the DMAC options granted?

The stock options granted to Charles Pauling Semba have an exercise price of $5.84 per share and expire on June 1, 2036. This means he may buy DiaMedica Therapeutics shares at $5.84 any time before the expiration date, subject to vesting.

How do the DiaMedica Therapeutics (DMAC) options granted to Semba vest?

The options granted to Charles Pauling Semba are scheduled to vest in four equal quarterly installments. This staggered vesting means he earns the right to exercise portions of the 40,412-share award over time, aligning the grant with continued service and retention.

Was this DiaMedica Therapeutics (DMAC) insider Form 4 a buy or a sale?

The Form 4 reports an acquisition via a grant, not a market trade. Charles Pauling Semba received 40,412 stock options as a compensation award, coded as a grant or award acquisition, with no open-market buying or selling of existing DiaMedica Therapeutics shares reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Semba Charles Pauling

(Last) (First) (Middle)

301 CARLSON PARKWAY

SUITE 210

(Street)

MINNEAPOLIS MINNESOTA 55305

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DiaMedica Therapeutics Inc. [ DMAC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$5.84	06/01/2026		A		40,412		(1)	06/01/2036	Voting Common Shares	40,412	$0	40,412	D

Explanation of Responses:

1. Scheduled to vest in four equal quarterly installments.

	/s/ Joshua L. Colburn, attorney-in-fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)